FOLD
Amicus Therapeutics Inc
Price Chart
No historical data available
Latest Quote
$14.49
Current Price| Open | $14.49 |
| Day High | $14.50 |
| Day Low | $14.49 |
| Volume | 5,285,334 |
Stock Information
| Shares Outstanding | 314.00M |
| Total Debt | $442.36M |
| Cash Equivalents | $293.54M |
| Revenue | $634.21M |
| Net Income | $-27.11M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.55B |
| EPS (TTM) | $-0.09 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.70B |
| Sales | $634.21M |
| Income | $-27.11M |
| Book/sh | $0.88 |
| Cash/sh | $0.93 |
| Employees | 511 |
Financial Ratios
| Quick Ratio | 1.72 |
| Current Ratio | 2.84 |
| Debt/Eq | 161.30 |
| EPS Growth TTM | -88.50% |
Returns & Margins
| ROA | 2.48% |
| ROE | -11.58% |
| Gross Margin | 88.50% |
| Operating Margin | 8.61% |
| Profit Margin | -4.28% |
Ownership
| Insider Ownership | 0.69% |
| Institutional Ownership | 104.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 17.69 |
| P/S | 7.17 |
| P/B | 16.43 |
Analyst Data
| Recommendation | hold |
| Target Price | $14.50 |
Technical Indicators
| SMA20 | $14.46 |
| SMA50 | $14.40 |
| SMA200 | $10.88 |
| RSI | 62.50 |
| ATR | 0.0157 |
| Shares Float | 311.44M |
| Short Float | 7.03% |
| Short Ratio | 6.36 |
| Volatility | 0.48 |
Performance History
| Week | +0.21% |
| Month | +0.42% |
| Quarter | +1.40% |
| 6 Months | +70.47% |
| YTD | +1.54% |
| Year | +101.25% |
| 3 Years | +26.00% |
| 5 Years | +48.01% |
| 10 Years | +145.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
đ° Latest News
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
Zacks âĸ 2026-05-05T17:17:00Z
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
MT Newswires âĸ 2026-05-05T15:13:30ZBioMarin acquires Amicus Therapeutics for $4.8bn
Pharmaceutical Technology âĸ 2026-04-28T09:51:54Z
CIBRA Capital Buys Stake in Allied Gold Stock
Motley Fool âĸ 2026-04-27T18:42:45Z
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Motley Fool âĸ 2026-04-25T15:33:12Z
Here is Why BioMarin (BMRN) is Projected to Rally
Insider Monkey âĸ 2026-03-31T07:18:53Z
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return
Simply Wall St. âĸ 2026-03-29T17:03:54Z
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
Zacks âĸ 2026-03-27T15:30:04Z
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
Investor's Business Daily âĸ 2026-03-26T17:04:56Z
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-03-26T15:30:07Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $72,929,000 | $52,943,000 | $37,326,000 | $38,599,000 |
| Cost Of Revenue | $72,929,000 | $52,943,000 | $37,326,000 | $38,599,000 |
| Total Revenue | $634,210,000 | $528,295,000 | $399,356,000 | $329,233,000 |
| Operating Revenue | $634,210,000 | $528,295,000 | $399,356,000 | $329,233,000 |
| Expenses | ||||
| Interest Expense | $46,159,000 | $49,598,000 | $50,149,000 | $37,119,000 |
| Total Expenses | $599,719,000 | $494,231,000 | $472,850,000 | $533,659,000 |
| Other Income Expense | $8,542,000 | $-18,629,000 | $-33,536,000 | $-3,518,000 |
| Other Non Operating Income Expenses | $10,244,000 | $-9,441,000 | $-15,886,000 | $4,176,000 |
| Net Non Operating Interest Income Expense | $-42,842,000 | $-44,191,000 | $-43,071,000 | $-34,095,000 |
| Interest Expense Non Operating | $46,159,000 | $49,598,000 | $50,149,000 | $37,119,000 |
| Operating Expense | $526,790,000 | $441,288,000 | $435,524,000 | $495,060,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
| Net Interest Income | $-42,842,000 | $-44,191,000 | $-43,071,000 | $-34,095,000 |
| Interest Income | $3,317,000 | $5,407,000 | $7,078,000 | $3,024,000 |
| Normalized Income | $-25,765,420 | $-48,847,480 | $-137,640,500 | $-229,027,880 |
| Net Income From Continuing And Discontinued Operation | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
| Total Operating Income As Reported | $32,789,000 | $24,876,000 | $-77,211,000 | $-212,120,000 |
| Net Income Common Stockholders | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
| Net Income | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
| Net Income Including Noncontrolling Interests | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
| Net Income Continuous Operations | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
| Pretax Income | $191,000 | $-28,756,000 | $-150,101,000 | $-242,039,000 |
| Special Income Charges | $-1,702,000 | $-9,188,000 | $-17,650,000 | $-7,694,000 |
| Interest Income Non Operating | $3,317,000 | $5,407,000 | $7,078,000 | $3,024,000 |
| Operating Income | $34,491,000 | $34,064,000 | $-73,494,000 | $-204,426,000 |
| Depreciation Amortization Depletion Income Statement | $7,460,000 | $8,547,000 | $7,873,000 | $5,342,000 |
| Depreciation And Amortization In Income Statement | $7,460,000 | $8,547,000 | $7,873,000 | $5,342,000 |
| Gross Profit | $561,281,000 | $475,352,000 | $362,030,000 | $290,634,000 |
| Per Share | ||||
| Diluted EPS | - | $-0.18 | $-0.51 | $-0.82 |
| Basic EPS | - | $-0.18 | $-0.51 | $-0.82 |
| Other | ||||
| Tax Effect Of Unusual Items | $-357,420 | $-1,929,480 | $-3,706,500 | $-153,880 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $55,512,000 | $38,577,000 | $-74,429,000 | $-191,884,000 |
| Total Unusual Items | $-1,702,000 | $-9,188,000 | $-17,650,000 | $-7,694,000 |
| Total Unusual Items Excluding Goodwill | $-1,702,000 | $-9,188,000 | $-17,650,000 | $-7,694,000 |
| Reconciled Depreciation | $7,460,000 | $8,547,000 | $7,873,000 | $5,342,000 |
| EBITDA (Bullshit earnings) | $53,810,000 | $29,389,000 | $-92,079,000 | $-199,578,000 |
| EBIT | $46,350,000 | $20,842,000 | $-99,952,000 | $-204,920,000 |
| Diluted NI Availto Com Stockholders | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
| Tax Provision | $27,301,000 | $27,350,000 | $1,483,000 | $-5,471,000 |
| Write Off | $1,702,000 | $0 | $1,134,000 | $6,616,000 |
| Restructuring And Mergern Acquisition | $0 | $9,188,000 | $2,583,000 | $1,078,000 |
| Research And Development | $135,843,000 | $109,362,000 | $152,381,000 | $276,677,000 |
| Selling General And Administration | $383,487,000 | $323,379,000 | $275,270,000 | $213,041,000 |
| Diluted Average Shares | - | $304,380,502 | $295,164,515 | $289,057,198 |
| Basic Average Shares | - | $304,380,502 | $295,164,515 | $289,057,198 |
| Other Special Charges | - | - | $13,933,000 | - |
Fetched: 2026-04-28
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $62,529,000 | $-20,950,000 | $-58,113,000 | $-97,750,000 |
| Total Assets | $949,870,000 | $785,033,000 | $777,880,000 | $724,167,000 |
| Total Non Current Assets | $273,697,000 | $280,297,000 | $294,819,000 | $300,351,000 |
| Other Non Current Assets | $13,739,000 | $13,641,000 | $18,553,000 | $19,242,000 |
| Goodwill And Other Intangible Assets | $211,712,000 | $214,995,000 | $218,287,000 | $220,797,000 |
| Other Intangible Assets | $13,915,000 | $17,198,000 | $20,490,000 | $23,000,000 |
| Current Assets | $676,173,000 | $504,736,000 | $483,061,000 | $423,816,000 |
| Other Current Assets | $38,511,000 | $34,909,000 | $49,533,000 | $40,209,000 |
| Inventory | $228,819,000 | $118,782,000 | $59,696,000 | $23,816,000 |
| Receivables | $115,307,000 | $101,099,000 | $87,632,000 | $66,196,000 |
| Accounts Receivable | $115,307,000 | $101,099,000 | $87,632,000 | $66,196,000 |
| Cash Cash Equivalents And Short Term Investments | $293,536,000 | $249,946,000 | $286,200,000 | $293,595,000 |
| Cash And Cash Equivalents | $214,010,000 | $213,752,000 | $246,994,000 | $148,813,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $178,650,000 | $176,359,000 | $140,864,000 | $243,177,000 |
| Total Debt | $442,363,000 | $443,644,000 | $445,059,000 | $452,120,000 |
| Long Term Debt And Capital Lease Obligation | $433,622,000 | $435,189,000 | $436,735,000 | $443,568,000 |
| Long Term Debt | $392,660,000 | $390,111,000 | $387,858,000 | $391,990,000 |
| Current Debt And Capital Lease Obligation | $8,741,000 | $8,455,000 | $8,324,000 | $8,552,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $675,629,000 | $590,988,000 | $617,706,000 | $601,120,000 |
| Total Non Current Liabilities Net Minority Interest | $437,801,000 | $442,286,000 | $450,017,000 | $462,102,000 |
| Other Non Current Liabilities | $4,179,000 | $7,097,000 | $13,282,000 | $18,534,000 |
| Current Liabilities | $237,828,000 | $148,702,000 | $167,689,000 | $139,018,000 |
| Other Current Liabilities | $11,678,000 | $12,491,000 | $10,371,000 | $7,465,000 |
| Payables And Accrued Expenses | $179,727,000 | $95,227,000 | $110,689,000 | $97,300,000 |
| Payables | $57,439,000 | $31,052,000 | $27,554,000 | $42,768,000 |
| Total Tax Payable | $28,809,000 | $18,105,000 | $12,434,000 | $5,938,000 |
| Accounts Payable | $28,630,000 | $12,947,000 | $15,120,000 | $15,413,000 |
| Interest Payable | - | $120,000 | $11,661,000 | $125,000 |
| Non Current Deferred Liabilities | - | - | - | $9,595,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | $4,939,000 |
| Other Payable | - | - | - | $21,417,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $274,241,000 | $194,045,000 | $160,174,000 | $123,047,000 |
| Total Equity Gross Minority Interest | $274,241,000 | $194,045,000 | $160,174,000 | $123,047,000 |
| Stockholders Equity | $274,241,000 | $194,045,000 | $160,174,000 | $123,047,000 |
| Gains Losses Not Affecting Retained Earnings | $24,109,000 | $5,095,000 | $5,241,000 | $-12,105,000 |
| Retained Earnings | $-2,767,290,000 | $-2,740,180,000 | $-2,684,074,000 | $-2,532,490,000 |
| Other Equity Interest | - | $71,000 | $71,000 | $83,000 |
| Other | ||||
| Treasury Shares Number | $7,390 | - | $0 | - |
| Ordinary Shares Number | $310,853,963 | $299,041,653 | $293,594,209 | $281,108,273 |
| Share Issued | $310,861,353 | $299,041,653 | $293,594,209 | $281,108,273 |
| Tangible Book Value | $62,529,000 | $-20,950,000 | $-58,113,000 | $-97,750,000 |
| Invested Capital | $666,901,000 | $584,156,000 | $548,032,000 | $515,037,000 |
| Working Capital | $438,345,000 | $356,034,000 | $315,372,000 | $284,798,000 |
| Capital Lease Obligations | $49,703,000 | $53,533,000 | $57,201,000 | $60,130,000 |
| Total Capitalization | $666,901,000 | $584,156,000 | $548,032,000 | $515,037,000 |
| Foreign Currency Translation Adjustments | $24,120,000 | $5,302,000 | $5,429,000 | $-11,989,000 |
| Unrealized Gain Loss | $-11,000 | $-207,000 | $-188,000 | $-116,000 |
| Treasury Stock | $71,000 | $0 | - | - |
| Additional Paid In Capital | $3,014,456,000 | $2,926,115,000 | $2,836,018,000 | $2,664,744,000 |
| Capital Stock | $3,037,000 | $2,944,000 | $2,918,000 | $2,815,000 |
| Common Stock | $3,037,000 | $2,944,000 | $2,918,000 | $2,815,000 |
| Long Term Capital Lease Obligation | $40,962,000 | $45,078,000 | $48,877,000 | $51,578,000 |
| Current Capital Lease Obligation | $8,741,000 | $8,455,000 | $8,324,000 | $8,552,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $37,682,000 | $32,529,000 | $38,305,000 | $25,701,000 |
| Current Accrued Expenses | $122,288,000 | $64,175,000 | $83,135,000 | $54,532,000 |
| Goodwill | $197,797,000 | $197,797,000 | $197,797,000 | $197,797,000 |
| Net PPE | $48,246,000 | $51,661,000 | $57,979,000 | $60,312,000 |
| Accumulated Depreciation | $-31,821,000 | $-28,775,000 | $-25,429,000 | $-22,281,000 |
| Leases | $33,067,000 | $32,361,000 | $28,032,000 | $24,162,000 |
| Construction In Progress | $0 | $262,000 | $3,810,000 | $4,160,000 |
| Other Properties | $36,909,000 | $38,498,000 | $42,532,000 | $45,879,000 |
| Machinery Furniture Equipment | $10,091,000 | $9,315,000 | $9,034,000 | $8,392,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $36,345,000 | $9,643,000 | $6,869,000 | $4,147,000 |
| Work In Process | $61,304,000 | $21,223,000 | $22,597,000 | $9,615,000 |
| Raw Materials | $131,170,000 | $87,916,000 | $30,230,000 | $10,054,000 |
| Other Short Term Investments | $79,526,000 | $36,194,000 | $39,206,000 | $144,782,000 |
| Land And Improvements | - | - | - | $0 |
Fetched: 2026-04-28
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $29,849,000 | $-37,444,000 | $-76,531,000 | $-170,341,000 |
| Operating Activities | ||||
| Operating Cash Flow | $33,145,000 | $-33,891,000 | $-69,091,000 | $-166,575,000 |
| Cash Flow From Continuing Operating Activities | $33,145,000 | $-33,891,000 | $-69,091,000 | $-166,575,000 |
| Operating Gains Losses | $3,586,000 | $16,234,000 | $33,546,000 | $6,121,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,296,000 | $-3,553,000 | $-7,440,000 | $-3,766,000 |
| Investing Cash Flow | $-46,432,000 | $-560,000 | $98,064,000 | $92,316,000 |
| Cash Flow From Continuing Investing Activities | $-46,432,000 | $-560,000 | $98,064,000 | $92,316,000 |
| Capital Expenditure Reported | $-3,296,000 | $-3,553,000 | $-7,440,000 | $-3,766,000 |
| Net Other Investing Changes | - | - | - | $3,411,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $19,566,000 | $92,935,000 | $0 |
| Financing Cash Flow | $610,000 | $5,121,000 | $61,677,000 | $-7,463,000 |
| Cash Flow From Continuing Financing Activities | $610,000 | $5,121,000 | $61,677,000 | $-7,463,000 |
| Net Other Financing Charges | $-18,323,000 | $-22,025,000 | $-20,573,000 | $-11,490,000 |
| Net Common Stock Issuance | $0 | $19,566,000 | $92,935,000 | $0 |
| Common Stock Issuance | $0 | $19,566,000 | $92,935,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-272,000 | $-97,000 | $-408,318,000 | $-283,000 |
| Issuance Of Debt | $0 | $0 | $387,360,000 | $0 |
| Interest Paid Supplemental Data | $43,608,000 | $58,960,000 | $36,090,000 | $34,358,000 |
| Income Tax Paid Supplemental Data | $14,894,000 | $8,214,000 | $8,525,000 | $1,069,000 |
| End Cash Position | $217,316,000 | $216,716,000 | $250,077,000 | $153,115,000 |
| Beginning Cash Position | $216,716,000 | $250,077,000 | $153,115,000 | $249,456,000 |
| Effect Of Exchange Rate Changes | $13,277,000 | $-4,031,000 | $6,312,000 | $-14,619,000 |
| Changes In Cash | $-12,677,000 | $-29,330,000 | $90,650,000 | $-81,722,000 |
| Proceeds From Stock Option Exercised | $19,205,000 | $7,677,000 | $10,273,000 | $4,310,000 |
| Net Issuance Payments Of Debt | $-272,000 | $-97,000 | $-20,958,000 | $-283,000 |
| Net Long Term Debt Issuance | $-272,000 | $-97,000 | $-20,958,000 | $-283,000 |
| Long Term Debt Payments | $-272,000 | $-97,000 | $-408,318,000 | $-283,000 |
| Long Term Debt Issuance | $0 | $0 | $387,360,000 | $0 |
| Net Investment Purchase And Sale | $-43,136,000 | $2,993,000 | $105,504,000 | $92,671,000 |
| Sale Of Investment | $51,269,000 | $117,779,000 | $197,227,000 | $335,926,000 |
| Purchase Of Investment | $-94,405,000 | $-114,786,000 | $-91,723,000 | $-243,255,000 |
| Change In Working Capital | $-39,633,000 | $-98,943,000 | $-26,643,000 | $-39,880,000 |
| Change In Other Working Capital | $-3,685,000 | $-3,248,000 | $-3,054,000 | $-4,636,000 |
| Change In Payables And Accrued Expense | $82,777,000 | $-16,520,000 | $49,195,000 | $-6,377,000 |
| Change In Payable | $82,777,000 | $-16,520,000 | $49,195,000 | $-6,377,000 |
| Change In Account Payable | $82,777,000 | $-16,520,000 | $49,195,000 | $-6,377,000 |
| Change In Prepaid Assets | $-1,382,000 | $13,961,000 | $-8,062,000 | $-6,194,000 |
| Change In Inventory | $-111,483,000 | $-73,652,000 | $-44,614,000 | $-5,343,000 |
| Change In Receivables | $-5,860,000 | $-19,484,000 | $-20,108,000 | $-17,330,000 |
| Changes In Account Receivables | $-5,860,000 | $-19,484,000 | $-20,108,000 | $-17,330,000 |
| Other Non Cash Items | $2,570,000 | $2,262,000 | $-16,148,000 | $3,712,000 |
| Stock Based Compensation | $87,410,000 | $84,905,000 | $86,077,000 | $76,512,000 |
| Asset Impairment Charge | $-1,138,000 | $9,210,000 | $2,727,000 | $18,177,000 |
| Deferred Tax | $0 | $0 | $-4,939,000 | $9,000 |
| Deferred Income Tax | $0 | $0 | $-4,939,000 | $9,000 |
| Depreciation Amortization Depletion | $7,460,000 | $8,547,000 | $7,873,000 | $5,342,000 |
| Depreciation And Amortization | $7,460,000 | $8,547,000 | $7,873,000 | $5,342,000 |
| Net Foreign Currency Exchange Gain Loss | $3,586,000 | $16,234,000 | $19,613,000 | $6,121,000 |
| Net Income From Continuing Operations | $-27,110,000 | $-56,106,000 | $-151,584,000 | $-236,568,000 |
Fetched: 2026-04-28